Bosutris 400mg Tablet

About

Bosutris 400mg Tablet, containing the active ingredient bosutinib, is a highly selective tyrosine kinase inhibitor (TKI) specifically developed for the treatment of chronic myeloid leukemia (CML). Its primary mechanism involves potent inhibition of the Bcr-Abl tyrosine kinase, an oncogenic protein that drives the uncontrolled proliferation of leukemic cells in CML. By blocking this crucial signaling pathway, bosutinib effectively suppresses the growth of malignant cells and induces their programmed cell death, leading to disease control and improved patient outcomes.

This targeted therapy is indicated for adult patients with newly diagnosed chronic phase Philadelphia chromosome-positive CML, or for those with chronic, accelerated, or blast phase CML who have demonstrated resistance or intolerance to prior TKI therapies. Bosutris offers a valuable treatment option for patients who have failed initial treatments. Due to its specific action, it provides a more precise approach to cancer management compared to conventional chemotherapy. However, close monitoring for potential adverse effects, particularly gastrointestinal issues, liver enzyme elevations, and fluid retention, is essential throughout the treatment duration.

Uses

• Chronic myeloid leukemia (CML)
• Philadelphia chromosome-positive CML
• CML resistant to prior therapy
• CML intolerant to prior therapy

Directions For Use

Take orally once daily with food as prescribed by your oncologist. Do not crush, cut, or chew the tablets.

Benefits

• Targets specific cancer pathways
• Effective in resistant CML cases
• Induces cancer cell apoptosis
• Helps control disease progression
• Oral administration for convenience
• Improved outcomes for CML patients

Side Effects

• Diarrhea
• Nausea and vomiting
• Abdominal pain
• Fatigue
• Rash
• Headache
• Elevated liver enzymes
• Fluid retention (edema)
• Myelosuppression (low blood counts)
• Kidney dysfunction
• Pancreatitis
• Cardiovascular events

Safety Measures

• Alcohol - Avoid or limit alcohol as it may exacerbate liver toxicity, a known side effect of Bosutris.
• Pregnancy - Contraindicated. Bosutris can cause fetal harm. Women of childbearing potential must use effective contraception.
• Breastfeeding - Not recommended. It is unknown if bosutinib is excreted in human milk, but potential for serious adverse reactions in infants exists.
• Liver - Use with caution and monitor liver function closely. Dose adjustments or interruption may be needed in hepatic impairment.
• Kidney - Use with caution and monitor renal function. Dose adjustments are required for moderate to severe renal impairment.
• Lung - Monitor for new or worsening pulmonary symptoms, as interstitial lung disease or pneumonitis can occur.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.